Business Wire

Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer

Del

Servier today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending LONSURF® (trifluridine/tipiracil), formerly known as TAS-102, for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

“The positive CHMP opinion for LONSURF marks our entry into the field of solid tumors, but more importantly, it is an important step forward in the treatment of patients with metastatic colorectal cancer,” said Patrick Therasse MD, PhD, Director & Head of Development, Oncology at Servier. “Patients with mCRC who do not respond to standard therapies currently have limited therapeutic options. The availability of an oral treatment that could help to extend overall survival will be an important advantage for patients.”

The CHMP positive opinion is based on data from the international, double-blind, placebo-controlled Phase III RECOURSE study, which investigated the efficacy and safety of LONSURF with best supportive care (BSC) compared to placebo with BSC in 800 patients with previously treated mCRC. The trial met the primary endpoint of statistically significant improvement in overall survival (OS). Results demonstrated a 32% reduction in risk of death compared to BSC (HR=0.68; 95% CI: 0.58 to 0.81 p<0.001) and an improvement of 1.8 months of median OS (median OS was 7.1 for LONSURF vs 5.3 months for placebo). The most frequently observed side effects (≥ 30%) in patients receiving LONSURF were neutropenia, nausea, fatigue, anemia and leucopenia.1,2

An updated OS analysis in 89% of events, this year presented at ASCO GI, confirmed the clinically meaningful and statistically significant survival benefit of LONSURF with BSC compared to placebo with BSC. This translates into a 31% relative reduction in the risk of death and an improvement of 2 months in the median OS. The median OS was 7.2 months for LONSURF with BSC vs 5.2 months for placebo with BSC (HR=0.69; 95% CI: 0.59 to 0.81; p<0.0001), this translated into 1-year survival rates of 27.1% and 16.6%, respectively.2,3

The CHMP positive opinion will now be reviewed by the European Commission and if marketing authorization is granted, LONSURF will be approved in the 28 member countries of the European Union (EU), as well as Iceland, Lichtenstein and Norway.

In June 2015, Servier entered into an exclusive license agreement with Taiho Pharmaceutical Co., Ltd. for the co-development and commercialization of LONSURF. Under the terms of the agreement, Servier will commercialize LONSURF in Europe and other countries outside of the United States, Canada, Mexico and Asia. Taiho Pharmaceutical retains the right to develop and commercialize LONSURF in the United States, Canada, Mexico, and Asia and to manufacture and supply the product.

About Metastatic Colorectal Cancer

There remains a high unmet need in the treatment of colorectal cancer (CRC), which was the second leading cause of cancer-related deaths in Europe in 2012, responsible for 215,000 deaths.4 Approximately 25% of patients with CRC present with metastases at initial diagnosis and almost 50% of patients with CRC will develop metastases.5 This contributes to the high mortality rates reported for CRC; the 5-year survival rate of patients diagnosed with stage IV mCRC is about 11%.6

About LONSURF

LONSURF is currently available in Japan for the treatment of unresectable advanced or recurrent CRC and in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine -, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.7,8 LONSURF is an oral combination anticancer drug of trifluridine (FTD) and tipiracil (TPI), whose primary mechanism of action differs from fluoropyrimidines. FTD is an antineoplastic nucleoside analog, which is incorporated directly into DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.

About Servier

Servier is an independent research-based pharmaceutical company headquartered in France. With a strong international presence in 148 countries and 92% of its medicines being prescribed outside of France, Servier employs more than 21,200 people worldwide. In 2015, the company recorded a turnover of 3.9 billion euros of which 24% was reinvested in research and development. Currently, there are nine new molecular entities in clinical development for oncology respectively in breast, lung and other solids tumors as well as various leukemias and lymphomas.

This portfolio of innovative cancer treatments is being developed with various partners worldwide, and covers different hallmarks of cancer including cytotoxics, proapoptotic, targeted, immune and cellular therapies.

1 Mayer RJ, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. N Engl J Med 2015; 372:1909-19.

2 LONSURF Summary of Product Characteristics

3 TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. J Clin Oncol 34, 2016 (suppl 4S; abstr 634) Available at: http://meetinglibrary.asco.org/content/159397-173 Accessed February 2016

4 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49: 1374–1403.

5 Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 25 (suppl 3): iii1-iii9.

6 American Cancer Society. Colorectal Cancer. Available at: http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-survival-rates Accessed February 2016

7 FDA News Release. FDA approves new oral medication to treat patients with advanced colorectal cancer. 22 September 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm Accessed February 2016

8 Taiho Pharma. Taiho's Lonsurf® (trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic Colorectal Cancer. Available at: http://www.taiho.co.jp/english/news/20140324.html Accessed February 2016

Contact information

Servier Communication Department
Justine Brodie
Tel: +44 203 808 6474
Email: presse@servier.fr
www.servier.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Alps Electric to Exhibit at Major Chinese Trade Show ELEXCON 201714.12.2017 06:00Pressemelding

Japanese electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (President: Toshihiro Kuriyama; Head Office: Tokyo) will exhibit at ELEXCON 2017, to be held at the Shenzhen Convention & Exhibition Center in Shenzhen, China, from December 21. The company will introduce a wide range of technologies, particularly in the Internet of Things (IoT) domain. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005033/en/ Alps Electric Booth Design (Graphic: Business Wire) At ELEXCON 2017, one of China’s largest electronics expositions, Alps Electric will showcase technologies and solutions targeting each of the Internet of Things (IoT), Mobile and Automotive markets. Exhibit Highlight: IoT Sensor Network Module A sensor module for collecting a variety of data,

Photo Press Release: Giant Gingerbread Burj Khalifa Unveiled at DXB14.12.2017 05:57Pressemelding

A 14 metre tall Burj Khalifa made of gingerbread takes centre stage at Dubai Airports’ Winter Wonderland DXB now open at Dubai International’s Terminal 3, B gates. “ Winter Wonderland DXB is the perfect way to get in the festive spirit just moments before jumping on a plane. An instagrammable village scene, set right in the middle of the airport, with entertainment for children and adults, visits from the main man in red on his sleigh and more!” said Helen Mellor-Mitchell, VP Media and Brand Engagement, Dubai Airports. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213006275/en/ Winter Wonderland DXB arrives at Dubai International Airport (Photo: AETOSWire) Editors Notes Dubai Airports manages the operation and development of both of

As Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies14.12.2017 05:20Pressemelding

Undersecretary-General Adama Dieng, United Nations Special Adviser on the Prevention of Genocide, announced a joint cooperation agreement between the United Nations and the Forum for Promoting Peace in Muslim Societies to organize ten research workshops to promote religious education in the Islamic world. Dieng said the agreement was attained following a set of previous meetings with His Excellency Shaykh Abdallah bin Bayyah, President of the Forum for Promoting Peace in Muslim Societies. Both parties discussed a potential cooperation between them to promote religious education via extensive academic programs, and agreed to organize ten research workshops the details of which shall be announced later. Dieng explained that the United Nations highly appreciates the efforts exerted by the Forum for Promoting Peace in Muslim Societies to promote tolerance and coexistence among p

Global Game Exhibition 'G-STAR 2017' Ends with a Big Finale14.12.2017 00:00Pressemelding

The global game exhibition ‘G-STAR 2017’ had attendees in 2,857 booths from 676 companies in 35 countries and was the largest ever held in history; amidst an enthusiastic response from industries and attendees it ended with a big finale. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005402/en/ G-STAR 2017 Public Area (Photo: Business Wire) ‘G-STAR 2017’ was hosted by the Korea Gaming Industry Association (K-GAMES) and managed by the G-STAR Organizing Committee and the Busan IT Industry Promotion Agency. It was held for four days from November 16 (Thursday) through November 19 (Sunday) at the Busan BEXCO. This was the 13th year for ‘G-STAR’, and it opened its doors to attendees with a variety of contents in an area approximately 55,300 square meters in size which included Exhib

IFF Declares Dividend for Fourth Quarter 201713.12.2017 21:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.69 per share of the Company’s common stock, payable on January 8, 2018 to shareholders of record as of December 29, 2017. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take a

Limelight Networks Enhances DDoS Security Services with Faster Mitigation of Malicious Website Attacks13.12.2017 19:18Pressemelding

Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, today introduced new capabilities to its DDoS Attack Interceptor Service that provide high-capacity on-network scrubbing and a scalable range of protection measures for web infrastructure, with the ability to easily increase protection as security requirements change. Protecting websites from online attacks and cyber threats is one of the most pressing security challenges today. For example, data from Limelight’s State of Cybersecurity Report: SE Asia shows consumers are very concerned about the security of ecommerce sites, with 72 percent saying they have a negative opinion of a brand after hearing that it has suffered a cyberattack. In addition, 51 percent of online websites feel they are vulnerable to attacks that could have significant financial and b

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom